Elekta AB (publ)
STO:EKTA B
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
61.8
87.8794
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Elekta AB (publ)
Elekta AB (publ)
Cash & Cash Equivalents
Elekta AB (publ)
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Elekta AB (publ)
STO:EKTA B
|
Cash & Cash Equivalents
kr2.8B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
S
|
Surgical Science Sweden AB
STO:SUS
|
Cash & Cash Equivalents
kr666.3m
|
CAGR 3-Years
29%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
CellaVision AB
STO:CEVI
|
Cash & Cash Equivalents
kr137.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
9%
|
|
|
Getinge AB
STO:GETI B
|
Cash & Cash Equivalents
kr2.7B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Arjo AB (publ)
STO:ARJO B
|
Cash & Cash Equivalents
kr923m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
S
|
Stille AB
STO:STIL
|
Cash & Cash Equivalents
kr97.9m
|
CAGR 3-Years
45%
|
CAGR 5-Years
20%
|
CAGR 10-Years
52%
|
|
Elekta AB (publ)
Glance View
Elekta AB operates as a medical technology company. The company is headquartered in Stockholm, Stockholm and currently employs 4,591 full-time employees. The firm offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer care. The firm has four product areas: Elekta Neuroscience, which develops solutions for the diagnosis and treatment of neurological diseases; Elekta Oncology, which creates clinical solutions for radiation therapy, such as linear accelerators, integrated imaging systems and clinical solutions for patient positioning and immobilization; Elekta Brachytherapy, which is engaged in the treatment of cancer through internal radiation, and Elekta Software, which develops software solutions for patient information, workflow management and treatment planning in oncology. The firm owns the service business of Asesores Electronicos Especializados SA de CV (AEESA).
See Also
What is Elekta AB (publ)'s Cash & Cash Equivalents?
Cash & Cash Equivalents
2.8B
SEK
Based on the financial report for Apr 30, 2024, Elekta AB (publ)'s Cash & Cash Equivalents amounts to 2.8B SEK.
What is Elekta AB (publ)'s Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
3%
Over the last year, the Cash & Cash Equivalents growth was 18%. The average annual Cash & Cash Equivalents growth rates for Elekta AB (publ) have been -8% over the past three years , 3% over the past five years .
You don't have any saved screeners yet
